PURPOSE: In the initial report of the Lupron Depot Neoadjuvant @entity263 Study Group @entity1 who received 3 months of @entity342 deprivation had a significant decrease in the positive margin rate. We monitored these @entity1 for 5 years and to our knowledge present the longest followup of any neoadjuvant trial. MATERIALS AND METHODS: A multi-institutional prospective randomized trial was performed between February 1992 and April 1994 involving @entity1 with stage cT2b @entity263 , including 138 who received 3 months of @entity3086 plus @entity12194 before radical prostatectomy and 144 who underwent radical prostatectomy only. @entity1 were followed every 6 months with serum @entity1486 ( @entity1486 ) testing for 5 years. Biochemical recurrence was defined as @entity1486 greater than 0.4 ng./ml. RESULTS: At 5 years there was no difference in the biochemical recurrence rate. @entity1486 was less than 0.4 ng./ml. in 64.8% of the @entity1 in the neoadjuvant @entity342 ablation plus prostatectomy and 67.6% in the prostatectomy only group (p = 0.663). CONCLUSIONS: Although 3 months of @entity342 deprivation before radical prostatectomy resulted in an apparently significant decrease in positive surgical margins, a 5-year followup does not indicate any difference in the recurrence rate. Until studies document improvement in biochemical or clinical recurrence with longer periods of treatment, induction @entity342 deprivation before radical prostatectomy is not indicated.

Neoadjuvant @entity342 ablation before radical prostatectomy in cT2bNxMo XXXX : 5-year results.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3086 :: ('MESH:D016729', 'Chemical') :: ['leuprolide'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'Prostate Cancer'] @entity12194 :: ('MESH:D005485', 'Chemical') :: ['flutamide'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity1486 :: ('354', 'Gene') :: ['PSA', 'prostate specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
